Company news
Context Therapeutics Inc. (NASDAQ:CNTX) news
Context Therapeutics Inc. news releases on 6ix. Latest, Jan 4, 2023: Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
Press releases — page 2
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
January 3, 2023
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
December 7, 2022
Context Therapeutics announces bispecific antibody clinical candidate to treat CLDN6+ cancers
December 5, 2022
Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors
November 28, 2022
Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium
November 20, 2022
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
November 8, 2022
Context Therapeutics® Amends Cash Guidance, Extends Runway into Q1 2024
September 26, 2022
Context Therapeutics® Reports Second Quarter 2022 Operating and Financial Results
August 10, 2022
Context Therapeutics and The Menarini Group Announce Clinical Trial Collaboration and Supply Agreement to Evaluate ONA-XR and Elacestrant Combination
August 1, 2022
Context Therapeutics® Reports First Quarter 2022 Operating and Financial Results
May 10, 2022
Context Therapeutics® Announces Poster Presentation at the Upcoming 2022 ASCO Annual Meeting
May 4, 2022
Context Therapeutics® Announces Encouraging Preclinical Data from Two Programs to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 10, 2022
Context Therapeutics® Reports Full Year 2021 Operating and Financial Results
March 22, 2022
Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2022
March 7, 2022
Context Therapeutics® Strengthens Research & Development Team
January 4, 2022
Context Therapeutics® Announces Positive Data from ONA-XR in Early Breast Cancer at 2021 San Antonio Breast Cancer Symposium
December 8, 2021
Context Therapeutics Inc. Announces Closing of $31.25 Million Private Placement
December 5, 2021
Context Therapeutics® Reports Third Quarter 2021 Operating and Financial Results
December 1, 2021
Context Therapeutics Inc. Announces $31.25 Million Private Placement
November 30, 2021
Context Therapeutics® Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Legal Officer
October 31, 2021
Context Therapeutics® and Wisconsin Oncology Network Announce First Patient Dosed in Phase 2 Trial of ONA-XR in Metastatic Breast Cancer
October 26, 2021
Context Therapeutics® Announces Closing of Initial Public Offering, Including Full Exercise of Underwriter’s Over-allotment Option
October 21, 2021